T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04220450

Enrollment

800

Registered

2020-01-07

Start date

2020-06-01

Completion date

2021-06-15

Last updated

2020-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease, Heart Failure, NAFLD, Valvular Disease

Brief summary

On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.

Interventions

DIAGNOSTIC_TESTT1 mapping on Cardiovascular Magnetic Resonance Studies

On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Months to No maximum

Inclusion criteria

* Referred for Cardiovascular Magnetic Resonance Imaging

Exclusion criteria

* Non-compatible Devices

Design outcomes

Primary

Measure	Time frame	Description
Correlation NAFLD and liver T1mapping	cross-sectional within one year	Correlation NAFLD risk score and liver T1-mapping (native and ECV9

Countries

Austria

Contacts

Primary ContactAndreas Kammerlander, MD PhD

andreas.kammerlander@meduniwien.ac.at0043 1 40400 46140

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026